Makani
Makani is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Makani.
Makani is a company.
Key people at Makani.
Makani Science, Inc. is a medtech portfolio company developing a wireless, wearable respiratory monitoring system to enable continuous, real-time tracking of breathing in clinical, home, and ambulatory settings.[1][4] The device, a stretchable postage-sized sensor with Bluetooth connectivity, serves healthcare professionals, patients, and applications like disease management, sleep apnea, pediatrics, sedation monitoring, and wellness, solving the problem of inaccessible, inaccurate respiratory data for earlier detection of issues and improved quality of life.[1][4] Recent milestones include FDA 510(k) clearance in April 2025 validating its safety, accuracy, and reliability across settings, an NIH grant for apnea of prematurity research, and acceptance into the FDA-funded CTIP pediatric innovation accelerator, signaling strong growth momentum.[1][4]
(Note: A separate entity, Makani (formerly Makani Power), focused on airborne wind energy kites but became independent within Alphabet around 2019 and appears inactive as a standalone company post-Google acquisition in 2013; this profile centers on the active Makani Science due to its recent advancements.)[2][3]
Makani Science emerged from over a decade of research at the University of California, Irvine, founded to commercialize reliable respiratory monitoring technology for clinical and home use.[1] The team's expertise in physiological measurements like lung function drove the creation of a comfortable, accurate wearable addressing gaps in traditional monitoring.[1] Pivotal early traction includes FDA 510(k) clearance for the Makani Respiratory Monitor in April 2025 after rigorous testing, an NIH grant for prematurity apnea studies, and selection into the CTIP accelerator, humanizing their push from academic innovation to real-world impact.[1][4]
Makani Science rides the remote patient monitoring and digital health wave, accelerated by post-pandemic demand for wearable diagnostics amid rising respiratory conditions like apnea and COPD.[1][4] Timing aligns with FDA's push for pediatric and home-based devices, where market forces favor non-invasive, scalable tech over bulky hospital equipment—global digital health wearables are projected to grow amid aging populations and chronic disease burdens.[1] They influence the ecosystem by advancing physiological monitoring standards, partnering with consortia like MTEC and CTIP to integrate into autonomous care, robotics, and behavioral health, potentially reducing hospital readmissions and enabling proactive interventions.[1]
Makani Science is poised for expansion post-FDA clearance, likely targeting partnerships with hospitals, telehealth platforms, and pediatric networks to scale adoption in apnea management and beyond.[1][4] Trends like AI-enhanced wearables and value-based care will shape their path, amplifying data-driven outcomes in respiratory health. Their influence may evolve from niche innovator to ecosystem enabler, powering broader physiological monitoring as NIH-backed research unlocks new uses—watch for commercial pilots and international clearances to fuel momentum from their accessible, life-improving tech.
Key people at Makani.
